IC
ICCM.US Icecure Medical
- Market cap
- USD 3.39M
- P/E
- -
- P/B
- 0.29x
- ROE
- -147.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is ICCM.US undervalued?
Graham numberThe Graham number of Icecure Medical cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Icecure Medical fundamental analysis
No fundamental analysis for Icecure Medical yet.
Icecure Medical stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Icecure Medical
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introd…
Full company profileIcecure Medical financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Icecure Medical annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 625K | 689K | 1.07M | 1.66M | 3.87M | 4.14M | 3.09M | 3.23M | 3.29M | 3.38M | 3.64M |
| Gross Profit | 221K | 175K | 449K | 576K | 2.44M | 2.20M | 1.45M | 1.30M | 1.45M | 1.23M | 1.10M |
| Operating Income | -3.10M | -2.66M | -3.17M | -4.61M | -4.14M | -9.72M | -16.7M | -15.6M | -15.7M | -15.1M | 354K |
| EBITDA | -3.03M | -2.75M | -3.42M | -4.60M | -4.08M | -9.43M | -16.3M | -15.3M | -15.4M | -14.8M | -17.1M |
| Net Income | -3.27M | -2.88M | -3.53M | -4.76M | -3.73M | -9.90M | -17.0M | -14.7M | -15.3M | -15.1M | -17.6M |
| EPS | -19 | -14 | -9.09 | -10 | -6.53 | -10 | -14 | -9.63 | -9.03 | -7.10 | -5.69 |
| Balance Sheet | |||||||||||
| Total Assets | 3.31M | 1.93M | 5.25M | 7.32M | 10.2M | 32.3M | 30.2M | 16.4M | 12.6M | 13.9M | 17.7M |
| Total Liabilities | 1.21M | 2.19M | 1.89M | 4.69M | 4.59M | 5.32M | 4.77M | 4.25M | 5.68M | 4.84M | 5.81M |
| Shareholders' Equity | 2.10M | -257K | 3.37M | 2.63M | 5.65M | 27.0M | 25.4M | 12.2M | 6.90M | 9.05M | 11.9M |
| Cash & Short-term Investments | 2.82M | 1.46M | 4.19M | 5.78M | 8.17M | 25.6M | 23.7M | 11.1M | 7.56M | 8.90M | 12.0M |
| Total Debt | - | 936K | - | 245K | 332K | 909K | 597K | 599K | 459K | 217K | 90.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -3.13M | -2.62M | -3.06M | -1.74M | -3.69M | -12.6M | -14.3M | -12.5M | -12.6M | -14.6M | -16.3M |
| Capital Expenditure | 22.9K | 8.63K | 64.3K | 102K | 223K | 533K | 891K | 480K | 71.0K | 36.0K | 122K |
| Free Cash Flow | -3.15M | -2.63M | -3.13M | -1.84M | -3.91M | -13.1M | -15.2M | -13.0M | -12.6M | -14.6M | -16.4M |
| Ratios | |||||||||||
| ROE | -155.5% | - | -105.0% | -181.3% | -66.0% | -36.7% | -66.8% | -120.5% | -222.0% | -166.4% | -147.5% |
| ROA | -98.7% | -148.9% | -67.3% | -65.1% | -36.4% | -30.7% | -56.2% | -89.3% | -121.8% | -108.4% | -99.1% |
| Net Profit Margin | -522.8% | -417.2% | -329.7% | -287.2% | -96.4% | -239.1% | -550.3% | -453.8% | -465.5% | -445.6% | -482.7% |
| Debt to Equity | - | - | - | 0.09x | 0.06x | 0.03x | 0.02x | 0.05x | 0.07x | 0.02x | 0.01x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Icecure Medical dividends
Icecure Medical has not paid dividends in the last 9 fiscal years.
Last stock split: 1:30 on Jun 4, 2026.
Who owns Icecure Medical
- Insiders 68.18%
- Institutions 13.78%
- Public & others 18.04%
- Shares outstanding 4.64M
- Free float 2.52M
Top funds holding ICCM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 40.5K | 0.04% | 0.00% | May 2026 |
Top institutions holding ICCM.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Jane Street Group LLC | 34.9K | 0.75% | 0.00% | Jun 2026 |
| Scientech Research LLC | 32.7K | 0.70% | 0.00% | Jun 2026 |
| Gunderson Capital Management Inc | 20.0K | 0.43% | +2,898.50% | Jun 2026 |
| UBS Group AG | 17.1K | 0.37% | +232.61% | Jun 2026 |
| HRT FINANCIAL LLC | 15.2K | 0.33% | +855.30% | Jun 2026 |
| JPMorgan Chase & Co | 5.95K | 0.13% | +2,905.05% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 4.33K | 0.09% | +664.37% | Jun 2026 |
| SBI Securities Co Ltd | 451.00 | 0.01% | 0.00% | Jun 2026 |
| Efficient Wealth Management LLC | 195.00 | 0.00% | 0.00% | Jun 2026 |
| BARTLETT & Co WEALTH MANAGEMENT LLC | 8.00 | 0.00% | 0.00% | Jun 2026 |
| Warberg Asset Management LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Janney Montgomery Scott LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Hudson Bay Capital Management LP | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Foundations Investment Advisors, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Lloyd Advisory Services, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Geode Capital Management, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Armistice Capital, LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
| Wellington Shields Capital Mgmt LLC | 0.00 | 0.00% | -100.00% | Jun 2026 |
Icecure Medical company profile
- Company name
- Icecure Medical
- Ticker
- ICCM.US
- ISIN
- IL0011224156
- Exchange
- USA Stocks
- Listed since
- Aug 26, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 67
- Fiscal year end
- December
- Address
- 7 Ha?Eshel St., Caesarea, Israel, 3079504
- Phone
- 972 4 623 0333
- Website
- icecure-medical.com
About Icecure Medical
IceCure Medical Ltd, a commercial-stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors in the United States, Japan, India, China, Israel, and internationally. The company offers the ProSense system, a single probe cryoablation system for the treatment of malignant breast tumors, as well as its associated disposables, including CryoProbes needles, and guiding needles/introducers; and IceSense3 system for ablation indications in urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MSense, a multi probe system for the treatment of multiple and larger tumors. The company serves hospitals, interventional radiological centers, ambulatory centers, and private clinics. IceCure Medical Ltd was incorporated in 2006 and is headquartered in Caesarea, Israel.
Icecure Medical management
7- Mr. Eyal ShamirCEO & Director · born 1961
- Mr. Shay LevavChief Operating Officer · born 1977
- Ms. Tlalit Bussi Tel-TzureVice President of Business Development & Global Marketing · born 1971
- Mr. Shad GoodVice President of Sales for North America · born 1978
- Mr. Meir PelegChief Financial Officer · born 1976
- Ms. Merav Nir DotanVice President of Human Resources · born 1969
- Ms. Galit MalikVice President of Operations & Service · born 1973